Page contentsKey factsDecisionTopicsKey facts Active Substance encequidar Therapeutic area Oncology Decision number P/0140/2021 PIP number EMEA-002913-PIP01-20 Pharmaceutical form(s) All pharmaceutical forms Condition(s) / indication(s) Treatment of breast cancerTreatment of soft tissue sarcoma Route(s) of administration All routes of administration Contact for public enquiries Athenex Inc.Tel.: +1 7164272860E-mail: pteegarden@athenex.com Decision type W: decision granting a waiver in all age groups for all conditions or indications Decision date 16/04/2021DecisionP/0140/2021 : EMA decision of 16 April 2021 on the granting of a product specific waiver for encequidar (EMEA-002913-PIP01-20)Reference Number: EMA/190360/2021 English (EN) (184.3 KB - PDF)First published: 17/01/2022ViewTopicsPaediatricsShare this page